The RLS Global Board of Directors has resolved to initiate a strategic review process to enable the commercial roll out of ChloraSolv across European markets.
The RLS Global Board of Directors will consider all strategic options, including a partnership, a sale of the company, a sale of ChloraSolv, or a financial investment in
"The review process will be undertaken with immediate effect, and we have set no timeline for completion of this process", says
"Bringing ChloraSolv to patients will require resources and capital that
TRADING PLACE AND CERTIFIED ADVISER:
FOR MORE INFORMATION, PLEASE CONTACT:
E-mail: larsakehjalmar@gmail.com
Phone: +46 70 588 81 90
Roland Frösing, acting CEO,
E-mail: roland.frosing@rlsglobal.se
Phone: +46 723 20 61 00
ABOUT
RLS's long-term vision is to be a leading research-driven platform company in wound care. The ambition is to expand into new indications through new research and development projects in areas such as wound care and dermatology. To maximize market presence, RLS works with partners to commercialize products globally. RLS is convinced that the company's platform technology and its unique features will help many patients around the world. Read more at rls.global
https://news.cision.com/rls-global-ab/r/rls-global-initiates-strategic-review-process-aiming-to-commercialize-chlorasolv,c3873106
(c) 2023 Cision. All rights reserved., source